炎症性疾病生物技术公司Invea Therapeutics(INAI.US)撤回3500万美元...

Group 1 - Invea Therapeutics, a clinical-stage biotech company developing oral small molecule drugs for inflammatory diseases, withdrew its initial public offering (IPO) plan due to market conditions [1] - The company had previously filed a prospectus to issue 3.2 million shares at a price range of $10 to $12 per share, aiming to raise $35 million [1] - Founded in 2021 and headquartered in Guilford, Connecticut, Invea Therapeutics planned to list on NASDAQ under the ticker symbol INAI [1] Group 2 - ThinkEquity was set to be the exclusive book-running manager for the IPO transaction [1]